Atara Biotherapeutics (ATRA) Projected to Post Earnings on Thursday

Atara Biotherapeutics (NASDAQ:ATRA) is expected to be releasing its earnings data before the market opens on Thursday, March 27th. Analysts expect Atara Biotherapeutics to post earnings of ($3.82) per share and revenue of $16.65 million for the quarter.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its earnings results on Friday, March 7th. The biotechnology company reported ($1.19) EPS for the quarter, topping the consensus estimate of ($3.82) by $2.63. The firm had revenue of $32.75 million during the quarter, compared to the consensus estimate of $20.58 million. On average, analysts expect Atara Biotherapeutics to post $-10 EPS for the current fiscal year and $-10 EPS for the next fiscal year.

Atara Biotherapeutics Price Performance

Shares of ATRA opened at $7.11 on Thursday. The company has a market capitalization of $41.66 million, a PE ratio of -0.28 and a beta of 0.49. Atara Biotherapeutics has a one year low of $5.40 and a one year high of $20.81. The company’s fifty day moving average price is $8.41 and its 200 day moving average price is $9.71.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on ATRA shares. TD Cowen upgraded shares of Atara Biotherapeutics to a “strong-buy” rating in a report on Friday, November 29th. HC Wainwright restated a “neutral” rating on shares of Atara Biotherapeutics in a report on Tuesday, January 28th. Canaccord Genuity Group restated a “buy” rating and set a $17.00 price objective on shares of Atara Biotherapeutics in a report on Tuesday, March 11th. Rodman & Renshaw started coverage on shares of Atara Biotherapeutics in a report on Friday, December 20th. They set a “buy” rating and a $25.00 price objective on the stock. Finally, RODMAN&RENSHAW downgraded shares of Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 21st. One investment analyst has rated the stock with a sell rating, three have given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.75.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.